secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001600620-26-000048
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q1 revenue $77.7M (+24% YoY), EPS $0.25 (+56%); reiterates FY guidance
------------------------------------------------------------------------------

- Net product sales of LUPKYNIS were $73.6M, up 23% YoY.
- Net income of $34.4M, up 48% YoY; diluted EPS $0.25 vs $0.16.
- Cash from operations surged to $32.6M from $1.3M a year ago.
- Repurchased 2.5M shares for $36.2M during Q1.
- Reaffirms 2026 total revenue guidance of $315M–$325M and net product sales of $305M–$315M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/0001600620-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/auph-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001600620-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer